KYMR
Kymera Therapeutics Inc
$29.88
Earnings Summary
Revenue | $9.62Mn |
Net Profits | $-36.68Mn |
Net Profit Margins | -381.25% |
Highlights
Kymera Therapeutics Inc’s revenue fell -48.55% since last year same period to $9.62Mn in the Q1 2022. On a quarterly growth basis, Kymera Therapeutics Inc has generated -37.01% fall in its revenue since last 3-months.
Kymera Therapeutics Inc’s net profit fell -180.57% since last year same period to $-36.68Mn in the Q1 2022. On a quarterly growth basis, Kymera Therapeutics Inc has generated -8.21% fall in its net profits since last 3-months.
Kymera Therapeutics Inc’s net profit margin fell -445.33% since last year same period to -381.25% in the Q1 2022. On a quarterly growth basis, Kymera Therapeutics Inc has generated -71.79% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Kymera Therapeutics Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.72 |
EPS Estimate Current Year | -0.72 |
Highlights
Kymera Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.72 - a -9.09% fall from last quarter’s estimates.
Kymera Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.72.
Key Ratios
Key ratios of the Kymera Therapeutics Inc post its Q1 2022 earnings
Earning Per Share (EPS) | -0.71 |
Return on Assets (ROA) | -0.18 |
Return on Equity (ROE) | -0.43 |
Dividend Per Share (DPS) | 0 |
Highlights
Kymera Therapeutics Inc’s earning per share (EPS) fell -144.83% since last year same period to -0.71 in the Q1 2022. This indicates that the Kymera Therapeutics Inc has generated -144.83% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Kymera Therapeutics Inc’s return on assets (ROA) stands at -0.18.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Kymera Therapeutics Inc’s return on equity (ROE) stands at -0.43.
Kymera Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-05-03 | -0.66 | -0.71 | -7.58% |
Company Information
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, which each address high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.
Organisation | Kymera Therapeutics Inc |
Headquarters | 200 Arsenal Yards Boulevard, Watertown, MA, United States, 02472 |
Employees | 75 |
Industry | Health Technology |